Videos

Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.

Mahsa Salsabili, PharmD, PhD, explores risk and value-based contracting for prescription digital therapeutics, along with strategies for manufacturers to support their utilization and optimization, while also delving into cost-effectiveness modeling and budget impact analysis.

Mahsa Salsabili, PharmD, PhD, offers a comprehensive list of factors for healthcare providers and payers to consider in order to streamline the process of prescription digital therapeutics to patients.

Physician shortages and retail pharmacy closures are creating areas without access to healthcare in rural regions and inner cities, warns Luke Greenwalt, vice president, market access, at IQVIA.

Newly launched drugs coming are facing payer controls and other hurdles, says Luke Greenwalt, vice president, market access, at IQVIA.

Mahsa Salsabili, PharmD, PhD, addresses the challenges surrounding insurance approval and the limited announcements regarding coverage for prescription digital therapeutics, while exploring various reimbursement models, such as value-based contracts and outcome-based rebates.

Mahsa Salsabili, PharmD, PhD, delves into the FDA approval process for prescription digital therapeutics , which requires market approval, clinical studies and real-world evidence, to establish their efficacy in treating the targeted disease or condition.

Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, discusses socioeconomic barriers, such as financial constraints, unstable housing, stressful living situations, and demanding work schedules, can hinder diabetes self-care, requiring healthcare providers to approach patients with empathy when addressing these challenges.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCC, discusses how technological advancements in diabetes care, such as continuous glucose monitors, can help patients better manage their disease.

Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.

Ross Margulies, J.D., M.P.H., a partner at the Foley Hoag law firm, discusses whether proposed transparency rules in the pharmacy benefit manager (PBM) legislation that Congress is considering might apply to the PBM-affiliated group purchasing organizations.

Mahsa Salsabili, PharmD, PhD, underscores the potential cost-effectiveness of treatment through the adoption of prescription digital therapeutics, while acknowledging that additional evidence is required to conclusively determine their cost-effectiveness.

A medical professional reviews the clinical application of prescription digital therapeutics in both monotherapy and adjunct therapy roles, emphasizing their potential for stand-alone treatment in substance abuse and other chronic illnesses, while also noting their complementary role in conjunction with other treatments as adjunct therapy.

The Access to Prescription Digital Therapeutics Act remains a top priority for the Academy of Managed Care Pharmacy (AMCP), according to Jennifer L. Mathieu, AMCP senior vice president of professional and government affairs.

A medical expert explores the development of prescription digital therapeutic models, including insurance investment in prescription digital therapeutics and telemedicine, as well as employer-sponsored benefits for non-prescription digital therapeutics and wellness initiatives aimed at improving overall health outcomes.

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

A medical professional examines the potential for cost-effective frontline treatments and personalized care delivered through a mobile application at the patient's own pace, emphasizing the significance of high self-motivation and patient activation, while also discussing the role of prescription digital therapeutics in adjunct therapy.

Mahsa Salsabili, PharmD, PhD, presents an overview of prescription digital therapeutics and their application in addressing unmet patient needs across various disease states, including diabetes, addiction, and mental health conditions.